medicationNot FDA-approvedPrescription only (US)Enclomiphene citrate has not received FDA approval as a standalone drug in the United States; the studied trials used investigational formulations under physician supervisionIt is available in the US only through compounding pharmacies with a prescription, not as an approved commercial product
Enclomiphene CitrateBenefits, Dosage & Interactions
Also known as: Androxal
Enclomiphene citrate is a non-steroidal estrogen receptor modulator (SERM). It is a chemical isomer of clomiphene citrate, where clomiphene often refers to a mixture of two isomers: enclomiphene and zuclomiphene. It is typically taken in the morning. The reported plasma half-life is about 10 hours, which shapes dosing frequency.
Researched by DoseRoutine R&D TeamReviewed for accuracy by Nicholas Alexander, RSELast updated
Evidence: Strong — 3 human randomized trials published.
Evidence strengthStrong · 4/4
PreclinicalStrong human evidence
3 human randomized trials published.
Plasma half-life
~10 h
Typical timing
morning
Default unit
mg
What published protocols report
Ranges documented in the literature, shown for reference. DoseRoutine does not recommend an amount — your prescriber or the product label sets the dose.
Reported for Enclomiphene Citrate in the cited sources. Published ranges are not dosing advice.
References & evidence
Documents the Enclomiphene Citrate entry is written from. Each number matches an inline marker above.
- [1]Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trialsHohl A, Chavez MP, Pasqualotto E, Ferreira ROM, Sande-Lee SV, Ronsoni MF · Archives of Endocrinology and Metabolism · 2025 · Peer-reviewed · PMID 41066380
- [2]Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized phase II clinical trial comparing topical testosteroneWiehle RD, Fontenot GK, Wike J, Hsu K, Nydell J, Lipshultz L · Fertility and Sterility · 2014 · Peer-reviewed · PMID 25044085
- [3]Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone: restoration instead of replacementKim ED, McCullough A, Kaminetsky J · BJU International · 2016 · Peer-reviewed · PMID 26496621
- [4]Oral enclomiphene citrate stimulates the endogenous production of testosterone and sperm counts in men with low testosterone: comparison with testosterone gelKaminetsky J, Werner M, Fontenot G, Wiehle RD · The Journal of Sexual Medicine · 2013 · Peer-reviewed · PMID 23530575
How to track Enclomiphene Citrate doses
Tracking Enclomiphene Citrate well takes four fields and a habit. Here is what to record so the log is still useful in three months.
- 1
Add the dose and unit
Log Enclomiphene Citrate with its dose in mg so totals stay comparable over time — including days when you split the dose or skip it.
- 2
Set the time of day and food rule
Typical timing is morning. Reminders fire at that time and can export to your calendar.
- 3
Check it against the rest of the stack
Run Enclomiphene Citrate through the interaction checker against everything else in the routine — supplements, peptides, hormones and prescriptions — before it becomes a daily habit.
- 4
Log adherence, not intentions
Mark each dose taken, skipped or delayed as it happens. Weeks of honest logs are what make an adherence rate or a trend line meaningful; retrospective guessing is not.
- 5
Review against outcomes
With a reported half-life around 10 h, effects and timing shifts show up over days rather than instantly. Review Enclomiphene Citrate alongside your logged metrics and any relevant blood work every few weeks before changing the dose.
What to log each time
- Dose in mg
- Time of day
- Taken / skipped / delayed
- Any side effects or notable changes
References & Evidence
Sources on this page that document Enclomiphene Citrate dosing, timing and safety.
- [1]National Center for Biotechnology Information View source
Educational information only — not medical advice. Dose ranges vary by person, indication and prescriber.
What is Enclomiphene Citrate?Sources for this section: Jumps to this entry in the sources and references list at the end of the page.
Enclomiphene citrate is a non-steroidal estrogen receptor modulator (SERM). It is a chemical isomer of clomiphene citrate, where clomiphene often refers to a mixture of two isomers: enclomiphene and zuclomiphene. While clomiphene has historically been used in fertility treatments for women, enclomiphene specifically has been investigated for its potential role in men's health, particularly in addressing secondary hypogonadism.
Unlike clomiphene, which contains both enclomiphene and zuclomiphene, enclomiphene is presented as a purified isomer. The presence of zuclomiphene, another isomer, is associated with a longer half-life and estrogenic effects that can potentially counteract some of the desired outcomes of enclomiphene. Enclomiphene's primary action is to selectively block estrogen receptors in the hypothalamus and pituitary gland, which are key regulatory centers for hormone production.
Enclomiphene is an orally administered medication and has been studied for its potential to increase endogenous testosterone production in men. Its development has focused on providing a treatment option for men with low testosterone levels who wish to maintain fertility, as it works by stimulating the body's natural hormone production rather than introducing exogenous testosterone. This mechanism is distinct from testosterone replacement therapy (TRT), which can often suppress natural testosterone production and impair sperm production.
What does the research say about Enclomiphene Citrate?
Tap a section to expand.
Enclomiphene citrate functions as a selective estrogen receptor modulator (SERM). Its primary mechanism of action involves antagonizing estrogen receptors in the hypothalamus and anterior pituitary gland. These two brain regions are crucial components of the hypothalamic-pituitary-gonadal (HPG) axis, which regulates testosterone production in men.
Normally, estrogen provides negative feedback to the hypothalamus and pituitary. When estrogen levels are perceived as high, the hypothalamus reduces its production of gonadotropin-releasing hormone (GnRH). GnRH, in turn, stimulates the anterior pituitary to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH is responsible for stimulating the Leydig cells in the testes to produce testosterone, while FSH is involved in spermatogenesis.
By blocking estrogen receptors in the hypothalamus, enclomiphene prevents estrogen from exerting its negative feedback. This leads to an increased pulsatile release of GnRH from the hypothalamus. The increased GnRH then stimulates the anterior pituitary to secrete more LH and FSH. The elevated LH levels subsequently stimulate the Leydig cells in the testes to produce more endogenous testosterone. Elevated FSH also supports spermatogenesis.
Crucially, enclomiphene's selective action means it primarily acts as an antagonist in these specific brain regions, thereby increasing the signaling pathways that lead to testosterone production, while potentially having different effects in other tissues. This targeted action is what differentiates it from broad estrogen receptor antagonists and makes it a potential treatment for secondary hypogonadism, where the problem lies in insufficient signaling from the brain, rather than a primary testicular failure. (DrugBank)
Source for this section: Sources for How does Enclomiphene Citrate work?: Jumps to this entry in the sources and references list at the end of the page.
Enclomiphene citrate has been primarily investigated for its potential benefits in men with secondary hypogonadism, a condition characterized by low testosterone levels due to impaired signaling from the brain (hypothalamus or pituitary gland) rather than a primary issue with the testes themselves. The main benefits explored include:
* **Increased Endogenous Testosterone Levels:** The core benefit of enclomiphene is its ability to stimulate the body's natural production of testosterone. By blocking estrogen receptors in the hypothalamus and pituitary, it reduces negative feedback, leading to increased release of LH and FSH, which in turn boosts testosterone production in the testes. This approach aims to normalize testosterone levels without introducing exogenous testosterone. (NIH ODS via clinical trials)
* **Maintenance of Spermatogenesis and Fertility:** Unlike traditional testosterone replacement therapy (TRT), which often suppresses endogenous testosterone production and can impair sperm production, enclomiphene's mechanism of action supports the continued function of the testes. By increasing FSH levels alongside LH, it helps maintain spermatogenesis, making it a potentially suitable option for men with hypogonadism who wish to preserve their fertility. (NIH ODS via clinical trials)
* **Improvement in Symptoms of Low Testosterone:** Normalizing testosterone levels can lead to improvements in various symptoms associated with hypogonadism, which may include enhanced libido, improved energy levels, better mood, and increased muscle mass and bone density. These symptomatic improvements are generally secondary to the increase in testosterone. (NIH ODS via clinical trials)
* **Potential for Muscle Development:** While not a primary use, by increasing testosterone levels, enclomiphene may indirectly support muscle development and maintenance in men with hypogonadism, consistent with the known effects of testosterone on anabolic processes. This falls under the general improvements expected from resolving low testosterone. (General understanding of testosterone's role, supported by studies on low T resolution).
Clinical trials have been conducted to evaluate the efficacy and safety of enclomiphene citrate, primarily focusing on its ability to increase testosterone levels in men with secondary hypogonadism. For example, studies published in sources referenced by NIH ODS have shown that enclomiphene can effectively increase serum total testosterone and luteinizing hormone (LH) levels in hypogonadal men. One Phase 3 trial reported an increase in total testosterone concentrations from a baseline of less than 300 ng/dL to a therapeutic range (300-1000 ng/dL) in a significant proportion of participants. These trials typically compared enclomiphene to placebo or other treatments.
Another aspect of the evidence concerns its differential effect compared to the mixed isomer clomiphene. Research highlights that the zuclomiphene isomer, present in standard clomiphene, has a much longer half-life and greater estrogenic activity, which can lead to accumulation and potentially undesirable side effects, or counteract the desired effects. Enclomiphene, as the purified isomer, aims to avoid these issues. (NIH ODS via clinical trials data and pharmacological studies).
However, it should be noted that while clinical trials demonstrated its effectiveness in raising testosterone and LH, enclomiphene citrate has not been approved by the FDA for any indication in the United States. Development programs were discontinued, primarily due to concerns related to clinical efficacy endpoints and the overall regulatory pathway, rather than overwhelming safety signals. Despite this, it remains a compound of interest in research and in some contexts is used off-label or via compounding pharmacies. (FDA communication and publicly available regulatory documents).
For example, studies have shown sustained elevation of testosterone levels after several weeks of daily administration, with corresponding increases in LH and FSH, indicating successful stimulation of the HPG axis without significant suppression of spermatogenesis, a key advantage over exogenous testosterone. (NIH ODS via clinical studies summary).
Clinical trials of enclomiphene citrate have reported various side effects, generally similar to those associated with other SERMs or compounds that modulate hormones. Common side effects may include:
* **Headache:** Mild to moderate headaches have been reported.
* **Nausea:** Gastrointestinal upset, including nausea, can occur.
* **Fatigue:** Some individuals may experience feelings of tiredness.
* **Vasomotor symptoms:** Hot flashes or flushing have been noted.
* **Mood changes:** Alterations in mood, including irritability or emotional lability.
* **Visual disturbances:** Although rare, visual changes (e.g., blurred vision, spots or flashes) have been associated with both enclomiphene and the parent compound clomiphene, warranting immediate medical attention if experienced.
* **Acne:** Due to increased testosterone, some individuals might experience an exacerbation of acne or new onset.
* **Testicular pain:** Less commonly reported, but some might experience discomfort in the testes.
It is important to promptly report any concerning or persistent side effects to a healthcare provider. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Given its impact on hormonal systems, several warnings are associated with the use of enclomiphene citrate:
* **Visual Symptoms:** Patients should be warned about the potential for visual disturbances, such as blurred vision, spots, or flashes. These symptoms can sometimes be persistent and necessitate immediate discontinuation and ophthalmologic evaluation. (Similar to clomiphene, MedlinePlus)
* **Ovarian Hyperstimulation Syndrome (OHSS):** While primarily a concern with clomiphene use in women for fertility, and enclomiphene is studied in men, the mechanism of action on gonadotropins means that it could theoretically, though highly unlikely in males, induce an exaggerated response if used inappropriately or in individuals with atypical hormone sensitivities. This is more of a general SERM-related warning.
* **Thromboembolic Events:** SERMs, including clomiphene, have been associated with an increased risk of thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism) in some populations. While direct evidence for enclomiphene in men is limited, individuals with a history or risk factors for blood clots should exercise caution. (General SERM class warning, MedlinePlus for clomiphene).
* **Undiagnosed Vaginal Bleeding (Not Applicable for Men):** This is a warning for clomiphene in women and is not relevant for men using enclomiphene.
* **Liver Function:** Caution should be exercised in individuals with impaired liver function, as the metabolism of enclomiphene is likely hepatic. (General pharmacological consideration).
* **Prolonged Use and Monitoring:** Due to its impact on the HPG axis, prolonged use requires regular monitoring of testosterone, LH, FSH, and estrogen levels to ensure appropriate hormonal balance and to detect any adverse shifts.
This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Several contraindications are generally considered for enclomiphene citrate, largely based on its mechanism of action and the contraindications for the parent compound clomiphene, or other SERMs:
* **Primary Testicular Failure:** Enclomiphene works by stimulating the testes to produce more testosterone. If the testes themselves are damaged or unable to respond (e.g., due to Klinefelter syndrome or severe testicular atrophy), enclomiphene will not be effective and is therefore generally contraindicated as it cannot overcome primary testicular dysfunction. Diagnosis by a clinician is necessary to differentiate between primary and secondary hypogonadism.
* **Uncontrolled Thyroid or Adrenal Dysfunction:** Uncorrected disorders of the thyroid or adrenal glands can mimic symptoms of hypogonadism or complicate hormonal regulation, making enclomiphene inappropriate until these conditions are managed. (General endocrine principle, MedlinePlus for clomiphene).
* **Known Hypersensitivity:** Individuals with a known allergy or hypersensitivity to enclomiphene citrate or any of its excipients should not use it.
* **Liver Disease:** Significant liver dysfunction may be a contraindication, as enclomiphene is metabolized in the liver. Impaired liver function could lead to accumulation of the drug or exacerbation of liver disease. (General pharmacological consideration).
* **Visual Impairment:** Due to the potential for visual disturbances, individuals with pre-existing visual conditions or those who develop visual symptoms should exercise caution or avoid use. (MedlinePlus for clomiphene).
* **Pituitary Tumor:** Any active or suspected pituitary tumor should be assessed and managed before considering enclomiphene, as it stimulates pituitary function and could theoretically exacerbate growth or symptoms of certain types of tumors. (MedlinePlus for clomiphene).
This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
When considering enclomiphene citrate, it's important to be aware of potential interactions with other substances due to its mechanism of action and impact on the endocrine system. While specific, robust drug-drug interaction studies for enclomiphene in men are not extensively published beyond general pharmacological principles, general considerations include:
* **Other Hormone Therapies:** Combining enclomiphene with other hormone-modulating drugs, especially those affecting the HPG axis (e.g., testosterone replacement therapy, hCG, aromatase inhibitors), should be done with extreme caution and under strict medical supervision. Concomitant use of exogenous testosterone would counteract enclomiphene's stimulatory effect on endogenous production by providing negative feedback to the HPG axis. (General endocrine interaction, Mayo Clinic for TRT).
* **Estrogen-Containing Medications or Phytoestrogens:** Since enclomiphene works by blocking estrogen receptors, substances that introduce exogenous estrogen or act as phytoestrogens (plant-derived compounds with estrogenic activity) could theoretically diminish its effectiveness by competing for receptor binding or overwhelming its antagonistic action. (General pharmacological principle).
* **Liver Enzyme Inducers/Inhibitors:** Drugs that significantly induce or inhibit cytochrome P450 enzymes, particularly those involved in enclomiphene's metabolism, could alter its plasma concentrations and effectiveness or increase the risk of side effects. Specific enzymes involved would need to be identified, but broad-spectrum inducers/inhibitors often require caution. (General pharmacological principle).
* **Medications Affecting Coagulation:** Given the potential for SERMs to interact with coagulation pathways, caution is advised when co-administering with anticoagulants (e.g., warfarin) or antiplatelet drugs. (General SERM class warning, MedlinePlus).
Always discuss all medications, supplements, and herbal products with a healthcare provider to avoid potential interactions. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
The typical timing for enclomiphene citrate is usually once daily, often taken in the morning. This consistency helps maintain stable blood levels of the compound. Its half-life is approximately 10 hours, supporting a once-daily dosing regimen to achieve sustained therapeutic effects on the hypothalamic-pituitary-gonadal axis. It can generally be taken with or without food, as food does not significantly impact its absorption. A licensed clinician will determine the appropriate dose and schedule based on individual needs and hormonal profiles.
Source for this section: Sources for When should you take Enclomiphene Citrate?: Jumps to this entry in the sources and references list at the end of the page.
What interacts with Enclomiphene Citrate?
| Interacts with | Severity | Type | What happens | What to do |
|---|---|---|---|---|
| Any supplement + medication | Note | Category ruleConfidence: theoretical | Some supplements change how the body processes medications (absorption, liver enzymes, or additive effects).Source pending | Specific pairs are checked against a licensed drug database and shown with their own severity. Always confirm with your provider or pharmacist. |
| Any vitamin + medication | Note | Category ruleConfidence: theoretical | Certain vitamins interact with specific medications (e.g., vitamin K with blood thinners).Source pending | Specific pairs are checked against a licensed source; confirm with your provider. |
Frequently asked questions about Enclomiphene Citrate
Enclomiphene Citrate is a medication. It is also known as Androxal. The references summarized come from NIH and PubMed records, FDA labeling where it exists, and Mayo Clinic patient material.
Enclomiphene Citrate is commonly discussed in the context of the goals discussed on its profile page. Individual response varies, and use should be reviewed with a licensed clinician who can weigh the benefits and risks for your situation.
For Enclomiphene Citrate, it is typically taken in the morning and its approximate half-life is 10 hours, which influences dosing frequency. Always follow the specific dose your clinician or the product label prescribes.
Enclomiphene Citrate carries potential side effects and drug interactions, documented in NIH, Mayo Clinic, and FDA label sources. Stop use and contact a clinician if you experience unexpected symptoms.
As a medication, Enclomiphene Citrate can overlap with other supplements, prescription medicines, hormones and peptides. Because Enclomiphene Citrate is usually taken in the morning, most avoidable conflicts come from what else lands in that same window. With a reported plasma half-life near 10 hours, separating doses can change the picture as much as removing one. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers Enclomiphene Citrate with no sign-up.
Whether Enclomiphene Citrate fits alongside testosterone replacement therapy depends on the protocol — dose, ester and ancillaries such as HCG or anastrozole — and on current bloodwork. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions
"Peptides" is not one category — healing peptides, GLP-1 agonists, growth-hormone secretagogues and melanocortins each behave differently next to Enclomiphene Citrate. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.
With a plasma half-life near 10 hours, once-daily dosing is the usual pattern for Enclomiphene Citrate. It is typically taken in the morning. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps
With a plasma half-life near 10 hours, a single missed dose of Enclomiphene Citrate usually has a smaller effect on overall exposure than an irregular pattern of missed doses does. Doubling up to "catch up" is generally not appropriate unless the label or prescriber says so. Follow the missed-dose instructions on your label or from your clinician, and log the miss so the pattern is visible later rather than forgotten.
For Enclomiphene Citrate the useful record is the dose, the time it was actually taken, and what else was taken in the same window. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.
Which studies looked at Enclomiphene Citrate?
Peer-reviewed research indexed in PubMed. Each entry links to the original record.
- 1.Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials(opens PubMed in a new tab)Arch Endocrinol Metab · 2025 · PMID 41066380 · https://pubmed.ncbi.nlm.nih.gov/41066380/
- 2.Enclomiphene citrate for the treatment of secondary male hypogonadism(opens PubMed in a new tab)Expert Opin Pharmacother · 2016 · PMID 27337642 · https://pubmed.ncbi.nlm.nih.gov/27337642/
- 3.Testosterone Restoration by Enclomiphene Citrate in Men with Secondary Hypogonadism: Pharmacodynamics and Pharmacokinetics.(opens PubMed in a new tab)BJU international · 2013 · PMID 23875626 · https://pubmed.ncbi.nlm.nih.gov/23875626/
- 4.Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized phase II clinical trial comparing topical testosterone(opens PubMed in a new tab)Fertil Steril · 2014 · PMID 25044085 · https://pubmed.ncbi.nlm.nih.gov/25044085/
- 5.Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone: restoration instead of replacement(opens PubMed in a new tab)BJU Int · 2016 · PMID 26496621 · https://pubmed.ncbi.nlm.nih.gov/26496621/
Sources cited on this page
Specific documents referenced by the numbered markers above. Each number matches the marker in the text.
- PubChem CID 6420009(opens in a new tab)National Center for Biotechnology Information · pubchem.ncbi.nlm.nih.gov/compound/6420009
Verify at
Publisher search links for Enclomiphene Citrate. These are places to check the information — they are not citations, so they are not numbered.
- DrugBank(publisher search, opens in a new tab)DrugBank Online · publisher search
- NIH Office of Dietary Supplements(publisher search, opens in a new tab)National Institutes of Health · publisher search
- MedlinePlus(publisher search, opens in a new tab)U.S. National Library of Medicine · publisher search
- Mayo Clinic(publisher search, opens in a new tab)Mayo Clinic · publisher search
- FDA-approved labeling (DailyMed)(publisher search, opens in a new tab)U.S. Food and Drug Administration · publisher search
- PubMed literature search(publisher search, opens in a new tab)National Library of Medicine · publisher search
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.
What is the short answer on Enclomiphene Citrate?
Plain-text summary, safe to quote verbatim:
Enclomiphene citrate is a non-steroidal estrogen receptor modulator (SERM). It is a chemical isomer of clomiphene citrate, where clomiphene often refers to a mixture of two isomers: enclomiphene and zuclomiphene. It is typically taken in the morning. The reported plasma half-life is about 10 hours, which shapes dosing frequency.
Source: DoseRoutine — https://doseroutine.com/library/enclomiphene-citrate
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). Enclomiphene Citrate — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/enclomiphene-citrate
What compounds are similar to Enclomiphene Citrate?
Others in the medication category or studied for the same goals.